Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03241186 · ClinicalTrials.gov registry record · Phase 2
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
A Phase 2 study of Mucosal Melanoma, sponsored by Robert R. McWilliams, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 7
- Study locations
NCT03241186 is a Phase 2 study of Mucosal Melanoma that is active but no longer recruiting, run by Robert R. McWilliams, MD. The registered enrollment target is 36 participants, below the 151-participant average among 12 other Mucosal Melanoma trials with a reported enrollment target (76% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT03241186, a Phase 2 study of Mucosal Melanoma, is active but no longer recruiting, sponsored by Robert R. McWilliams, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with resected mucosal melanoma. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) will be administered Day 1 of a 21-day cycle in Cycles 1-4 and then nivolumab 480 mg will be administered Day 1 of a 28-day cycle for Cycles 5-15 (maximum of 15) or until disease recurrence or intolerance before completion of 15 cycles.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Study Locations (7)
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic Rochester - Rochester
Florida
- Mayo Clinic- Florida - Jacksonville
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Nebraska
- Nebraska Cancer Specialists - Omaha
Oregon
- Providence Portland Medical Center - Portland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-09-12 |
| Est. Completion | 2023-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03241186
The ClinicalTrials.gov registry entry for NCT03241186 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 12 other Mucosal Melanoma trials with a reported enrollment target (76% lower). The listed sponsor is Robert R. McWilliams, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mucosal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03241186 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Minnesota, Florida, Iowa.
Frequently Asked Questions
What is clinical trial NCT03241186 about?
NCT03241186 is a clinical study titled "Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma". This is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with resected mucosal melanoma. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) will be administered Day 1 of a 21-day cycle in Cycles 1-4 and then nivolumab 480 mg will be administered Day 1 of a 28-day cycle for Cycl...
What is the current status of trial NCT03241186?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-09-12. Estimated completion is 2023-09.
What conditions does trial NCT03241186 study?
This clinical trial studies the following conditions: Mucosal Melanoma.
What interventions are being tested in trial NCT03241186?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03241186?
This trial is sponsored by Robert R. McWilliams, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03241186 being conducted?
This trial has 7 study locations across Florida, Iowa, Minnesota, Nebraska, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucosal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
RECRUITING · Phase 2
-
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.